Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Adrian J, Santiago Ortiz"'
Autor:
Elisabetta Patorno, Mehdi Najafzadeh, Ajinkya Pawar, Jessica M. Franklin, Anouk Déruaz‐Luyet, Kimberly G. Brodovicz, Adrian J. Santiago Ortiz, Lily G. Bessette, Martin Kulldorff, Sebastian Schneeweiss
Publikováno v:
Endocrinology, Diabetes & Metabolism, Vol 3, Iss 1, Pp n/a-n/a (2020)
Abstract Background The EMPA‐REG OUTCOME trial showed that empagliflozin reduced the risk of cardiovascular death and hospitalization for heart failure (HHF) in diabetic patients with cardiovascular disease. EMPRISE is a study programme on the effe
Externí odkaz:
https://doaj.org/article/3b1d4ccae1a34e5da8d6f66e7b2e3401
Autor:
Seoyoung C. Kim, Soo Kyung Cho, Angela Y. Tong, Adrian J. Santiago Ortiz, Yinzhu Jin, Tracy J. Doyle, Jeffrey A. Sparks, Hemin Lee
Publikováno v:
Seminars in Arthritis and Rheumatism. 50:592-597
Objective To develop and validate claims-based algorithms to identify interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) Methods Using Medicare claims data linked with the electronic medical records (2012-2014), we first selec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54b3c8314663817f7d35ad8ee98b35af
https://doi.org/10.1016/j.semarthrit.2020.04.006
https://doi.org/10.1016/j.semarthrit.2020.04.006
Autor:
James Marshall, Aaron B. Mendelsohn, Seoyoung C. Kim, Mengdong He, Charles E. Barr, Adrian J. Santiago Ortiz, Jeffrey R. Curtis, Catherine M Lockhart
Publikováno v:
Pharmacoepidemiology and Drug Safety. 29:770-777
Purpose The Centers for Medicare and Medicaid Services (CMS) mandated the transition from ICD-9 to ICD-10 codes on October 1, 2015. Postmarketing surveillance of newly marketed drugs, including novel biologics and biosimilars, requires a robust appro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48397ef6aaf786d2f3c78c44fa332c0c
https://doi.org/10.1002/pds.4933
https://doi.org/10.1002/pds.4933
Autor:
Soo Kyung Cho, Hemin Lee, Angela Y. Tong, Seoyoung C. Kim, Yinzhu Jin, Julia A. Ford, Adrian J. Santiago Ortiz
Publikováno v:
Pharmacoepidemiology and Drug Safety. 29:404-408
PURPOSE An increasing number of new medications are being developed and approved for psoriatic arthritis (PsA). To generate real-world evidence on comparative safety and effectiveness of these drugs, a claims-based algorithm that can accurately ident
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be9fa3133a5057094853c196d04f62e0
https://doi.org/10.1002/pds.4950
https://doi.org/10.1002/pds.4950
Autor:
Barbara Mintzes, Mathias Møllebæk, Nileesa Gautam, Alice Bhasale, Ameet Sarpatwari, Eliza J. McEwin, Wendy Lipworth, Adrian J. Santiago Ortiz
Publikováno v:
British Journal of Clinical Pharmacology
Aims Medicines regulators issue post-market safety warnings to advise of newly uncovered risks, but with mixed impacts. We aimed to identify factors influencing the use of regulatory warnings by primary care and specialist physicians in the US and Au
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f7e6cfc48c4884d610d21e5dd27d9ae
https://pubmed.ncbi.nlm.nih.gov/34337777
https://pubmed.ncbi.nlm.nih.gov/34337777
Autor:
Mehdi Najafzadeh, Martin Kulldorff, Adrian J. Santiago Ortiz, Lily G. Bessette, Steven Sambevski, Anouk Deruaz-Luyet, Ajinkya Pawar, Kimberly G. Brodovicz, Sebastian Schneeweiss, Elisabetta Patorno, Jessica M. Franklin
Publikováno v:
Circulation. 139:2822-2830
Background: The EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 diabetes Mellitus Patients) showed that empagliflozin, a sodium-glucose cotransporter-2 inhibitor, reduces the risk of hospitalization for heart failur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ace2562c68e1043299358d43acf4059
https://doi.org/10.1161/circulationaha.118.039177
https://doi.org/10.1161/circulationaha.118.039177
Autor:
Ameet, Sarpatwari, Beatrice L, Brown, Sarah A, McGraw, Sara Z, Dejene, Abdurrahman, Abdurrob, Adrian J, Santiago Ortiz, Aaron S, Kesselheim
Publikováno v:
JAMA Network Open
This qualitative study examines patient and caregiver experiences with and perceptions of Risk Evaluation and Mitigation Strategy programs with Elements to Assure Safe Use.
Key Points Question How do patients and caregivers describe their experi
Key Points Question How do patients and caregivers describe their experi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1250ad2afc3a43aecf72801eedf9457f
https://doi.org/10.1001/jamanetworkopen.2021.44386
https://doi.org/10.1001/jamanetworkopen.2021.44386
Autor:
Robert J. Glynn, Jerome Avorn, Sebastian Schneeweiss, Adrian J. Santiago Ortiz, Martin Kulldorff, Alexis A. Krumme, Niteesh K. Choudhry, Joshua J. Gagne, Ajinkya Pawar
Publikováno v:
Journal of Comparative Effectiveness Research. 7:57-66
Since 2010, four oral anticoagulants have been approved for marketing in addition to warfarin for treatment of thromboembolic disease. Limited head-to-head data exist comparing these treatments, leaving patients and clinicians with little guidance fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed620cd0a19ca190dc2c42e8bb34624a
https://doi.org/10.2217/cer-2017-0053
https://doi.org/10.2217/cer-2017-0053
Autor:
Ajinkya Pawar, Sebastian Schneeweiss, Jessica M. Franklin, Mehdi Najafzadeh, Kimberly G. Brodovicz, Adrian J. Santiago Ortiz, Elisabetta Patorno, Lily G. Bessette, Anouk Deruaz-Luyet, Martin Kulldorff
Publikováno v:
Endocrinology, Diabetes & Metabolism
Endocrinology, Diabetes & Metabolism, Vol 3, Iss 1, Pp n/a-n/a (2020)
Endocrinology, Diabetes & Metabolism, Vol 3, Iss 1, Pp n/a-n/a (2020)
Background The EMPA‐REG OUTCOME trial showed that empagliflozin reduced the risk of cardiovascular death and hospitalization for heart failure (HHF) in diabetic patients with cardiovascular disease. EMPRISE is a study programme on the effectiveness
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd5deff04648260c9321a7db98716853
http://europepmc.org/articles/PMC6947693
http://europepmc.org/articles/PMC6947693
Autor:
Chandrasekar Gopalakrishnan, Krista F. Huybrechts, Sebastian Schneeweiss, Adrian J. Santiago Ortiz, Dorothee B. Bartels, Kristina Zint
Publikováno v:
Journal of thrombosis and haemostasis : JTH. 17(7)
Essentials Unlike warfarin, treatment with DOACs do not require regular plasma level monitoring. We compared persistence of patients treated with DOACs compared to warfarin. Persistence at 12 months was higher for all DOACs compared to warfarin. Pers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a5dbdf89dc8a251d6d955b83fb5cf0c
https://pubmed.ncbi.nlm.nih.gov/31038824
https://pubmed.ncbi.nlm.nih.gov/31038824